Crossmark

Pharmacovigilance analysis and real-world adverse event profile (safety signals and product-related issues) of potassium citrate: a US FDA adverse event reporting system (FAERS) based analysis

Crossref DOI link: https://doi.org/10.1007/s00240-026-01989-0

Published Online: 2026-04-28

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ergül, Rifat Burak

Gürlek, Ismail Taha

Yitgin, Yasin

Ozcan, Seyda Gül

Özervarlı, M. Fırat

Turan, Serdar

Verep, Samed

Şenel, Samet

Atar, Arda

Kiremit, Muratcan

Pietropaolo, Amelia

Gökçe, M. İlker

Somani, Bhaskar

Sarica, Kemal

Tefik, Tzevat
Funding

Funding for this research was provided by:

Istanbul University
License Information

Text and Data Mining valid from 2026-04-28

Version of Record valid from 2026-04-28
More Information

Article History

Received: 28 August 2025

Accepted: 5 April 2026

First Online: 28 April 2026

Declarations

:

: None of the authors have any disclosures to state.

: Not applicable. This study used anonymized, publicly available data from the FDA Adverse Event Reporting System (FAERS), therefore ethics approval was not required.

: Not applicable.

: During the preparation of this work, the authors used AI in order to improve the readability and language of the manuscript. After using this tool, the authors reviewed and edited the content as needed and takes full responsibility for the content of the publication.

Document is current

Any future updates will be listed below